Core Viewpoint - The approval of VELSIPITY® for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Company Developments - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY® (Arginine Acquimod Tablets) [1] - The company plans to actively prepare for the commercialization of VELSIPITY® and aims to expedite its availability to domestic patients while promoting its inclusion in the national medical insurance catalog [1] Strategic Goals - The approval of VELSIPITY® is part of the company's broader 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create both certain commercial value and growth-oriented research and development value [1] - The company intends to continue strengthening its core therapeutic area advantages, advancing innovative drug research and commercialization, and establishing itself as a sustainable growth global innovative biopharmaceutical enterprise [1]
港股异动 | 云顶新耀(01952)午后曾涨超5% 维适平新药上市申请获国家药监局批准